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Abstract
Several naphthalimides have been evaluated clinically as potential anticancer agents. UNBS3157, a naphthalimide
that belongs to the same class as amonafide, was designed to avoid the specific activating metabolism that in-
duces amonafide’s hematotoxicity. The current study shows that UNBS3157 rapidly and irreversibly hydrolyzes to
UNBS5162 without generating amonafide. In vivo UNBS5162 after repeat administration significantly increased
survival in orthotopic human prostate cancer models. Results obtained by the National Cancer Institute (NCI) using
UNBS3157 and UNBS5162 against the NCI 60 cell line panel did not show a correlation with any other compound
present in the NCI database, including amonafide, thereby suggesting a unique mechanism of action for these two
novel naphthalimides. Affymetrix genome-wide microarray analysis and enzyme-linked immunosorbent assay re-
vealed that in vitro exposure of PC-3 cells to UNBS5162 (1 μM for 5 successive days) dramatically decreased the
expression of the proangiogenic CXCL chemokines. Histopathology additionally revealed antiangiogenic properties
in vivo for UNBS5162 in the orthotopic PC-3 model. In conclusion, the present study reveals UNBS5162 to be a
pan-antagonist of CXCL chemokine expression, with the compound displaying antitumor effects in experimental
models of human refractory prostate cancer when administered alone and found to enhance the activity of taxol
when coadministered with the taxoid.
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Introduction
Naphthalimides, a class of compounds that bind to DNA by inter-
calation, have shown high anticancer activity against a variety of mu-
rine and human tumor cells [1]. One early representative, amonafide,
was evaluated in clinical trials as a potential anticancer agent [1] but
failed to enter phase III because of dose-limiting bone marrow toxicity
leading to thrombocytopenia, anemia, and leucopenia. This toxicity is
linked to its metabolism through a polymorphic enzyme (N-acetyl
transferase 2) to a toxic metabolite, N-acetyl-amonafide [2,3]. The
therapeutic properties of naphthalimides were subsequently improved
by designing bis-intercalating agents [4,5]. One of these, elinafide,
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which revealed marked in vitro and in vivo activities, has also been
evaluated in clinical trials against solid tumors [1,6]. Further novel
amonafide analogues continue to be evaluated in experimental cancer
models [7]. We ourselves designed a novel naphthalimide derivative,
UNBS3157, to avoid the metabolism that provokes the clinical hema-
totoxicity of amonafide [8]. Accordingly in mice, UNBS3157 was
found to have a three- to four-fold higher maximum tolerated dose
irrespective of administration route and was found not to provoke he-
matotoxicity at therapeutic doses in mice unlike amonafide [8]. Fur-
thermore, UNBS3157 proved to be superior to amonafide in vivo in
models of 1) L1210 murine leukemia, 2) MXT-HI murine mammary
adenocarcinoma, and 3) orthotopic models of human A549 non–small
cell lung cancer and Bx-PC-3 pancreatic cancer [8]. In the current
study, we report that UNBS3157 is rapidly and almost totally hydro-
lyzed in physiological saline into one single product, UNBS5162,
which accounts for the anticancer activity. The aim of the present
study was to investigate the overall mechanism of action of UNBS5162
in the specific context of human prostate cancer, both in vitro and
in vivo, given that recent research [7,9] and clinical data [10] continue
to emphasize the potential of amonafide and its derivatives to combat
prostate cancers.
Materials and Methods
Cell Lines and Media
Human cancer cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, VA), the European Collection
of Cell Culture (ECACC, Salisbury, UK), and the Deutsche Samm-
Lung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig,
Germany). The cell lines evaluated were the Hs683 (ATCC code
HTB-138) and U373-MG (ECACC code 89081403) glioblastomas,
the HCT-15 (DSMZ code ACC357) and LoVo (DSMZ code ACC350)
colon cancers, the Bx-PC-3 (ATCC code CRL-1687) pancreatic
cancer, the A549 (DSMZ code ACC107) non–small cell lung can-
cer, the MCF-7 (DSMZ code ACC115) breast cancer, and the PC-3
(ATCC code CRL1435) and DU-145 (ATCC code HTB81) pros-
tate cancers. Cell lines were maintained according to the suppliers’ in-
structions. The cells were incubated at 37°C in sealed (airtight) Falcon
plastic dishes (Nunc, Invitrogen SA, Merelbeke, Belgium) in a 5%
CO2 atmosphere.
Compounds
UNBS3157, UNBS5181, UNBS5162, and amonafide were pre-
pared at Unibioscreen laboratories as detailed elsewhere [8]. Reference
drugs were obtained as follows: taxol (Paclitaxel; S.A. Bristol-Myers
Squibb, Brussels, Belgium), mitoxantrone (Sigma, Bornem, Belgium),
doxorubicin (Adriamycin; Pfizer Pharmacia, Puurs, Belgium), and te-
mozolomide (TMZ; Schering Plough, Brussels, Belgium).
Evaluation of In Vitro Cell Proliferation By Means of the
MTT Colorimetric Assay
The overall growth of human cancer cell lines was determined by
means of the colorimetric MTT (3-[4,5-dimethylthiazol-2yl]-diphenyl
tetrazolium bromide; Sigma) assay, as detailed previously [8,11].
Flow Cytometry Analysis of Cell Cycle Kinetics
The cell cycle kinetics of prostate cancer cells left untreated or
incubated with UNBS5162 were determined by flow cytometry
analysis of propidium iodide (PI) nuclear staining, using previously
detailed methodology [12,13]. Each sample was evaluated in tripli-
cate. Flow cytometry was undertaken using an Epics XL.MCL flow
cytometer and the FACScan/CellQuest software system (Becton
Dickinson, Miami, FL).
Flow Cytometry Analysis for Apoptosis Determination
The determination of the percentage of cells undergoing apoptosis
was performed using an Annexin V–FITC Apoptosis Detection Kit
(Sigma) following the manufacturer’s instructions as detailed previ-
ously [8,12]. Each sample was evaluated in triplicate.
Flow Cytometry Analysis for Autophagy Determination
Autophagic effects of UNBS5162 were determined by quantifying
acidic vesicular organelles (revealed as red fluorescence) after acridine
orange (Sigma) staining of PC-3 or DU-145 cells. The cytoplasm
and nucleus fluoresce green in acridine orange–stained cells, and
the acidic compartments fluoresce red. The intensity of the red fluo-
rescence is proportional to the degree of acidity and the volume of
acidic vesicular organelles, including autophagic vacuoles. To quantify
the development of acidic vesicular organelles, the cells were stained
with acridine orange for 15 minutes and removed from the plate with
trypsinization. Cells were then analyzed by flow cytometry. Each sam-
ple was evaluated in triplicate.
Cell Senescence Analysis
After the indicated treatments, cells were washed in PBS, fixed
for 3 to 5 minutes (at room temperature) in 2% formaldehyde/
0.2% glutaraldehyde, washed and incubated at 37°C (in the absence
of CO2) with fresh senescence-associated β-Gal (SA-β-Gal) stain-
ing solution: 1 mg/ml of 5-bromo-4-chloro-3-indolyl P3-d-galactoside
(X-Gal; Sigma). Staining was evident within 2 to 4 hours and maximal
after 12 to 16 hours. To detect lysosomal β-Gal, the citric acid/sodium
phosphate used was pH 4.0. As described in the study of Dimri et al.
[14], after fixing and staining with X-Gal, the number of cells positive
for the SA-β-Gal activity (intense blue staining) was then counted in-
dependently by two different individuals (on 400 cells/plate). Repre-
sentative photographs (original magnifications, ×20) of stained cells
from different experimental treatments were taken. As a positive con-
trol for SA-β-Gal expression, Adriamycin-treated cells were used.
Total RNA Extraction
Total RNA was extracted using the TRIzol isolation reagent (Life
Technologies, Inc., Merelbeke, Belgium) according to the manufac-
turer’s instructions. The RNA extracted was treated with DNase I (Life
Technologies, Inc.) to eliminate any remaining genomic DNA. The
quality and integrity of the extracted RNA were assessed using both
the BioAnalyzer 2100 (Agilent, Toulouse, France) and gel electrophoresis.
Quantitative (Real-time) Reverse Transcription–Polymerase
Chain Reaction (RT-PCR)
Reverse transcription reactions were carried out in a thermal cycler
(Thermocycler; Westburg, Leusden, The Netherlands). The purifica-
tion of the cDNAs produced was undertaken using the High Pure
PCR Product Purification Kit (Roche Diagnostics, Mannheim, Ger-
many) in accordance with the manufacturer’s instructions. Quantita-
tive PCR reactions were performed with 50 ng of purified cDNA in a
LightCycler thermocycler instrument (Roche Diagnostics) using LC-
Fastart DNA Master SYBR Green 1 (Roche Diagnostics). After am-
plification, data analysis was carried out by means of the “Fit points”
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algorithm of the LightCycler quantification software. A standard
curve enabled cDNA quantification of samples to be effected. The
primers used were provided by Invitrogen and selected using the
HYBSIMULATOR software (Advanced Gene Computing Technology,
Irvine, CA). The primers used were as follows: ets homologous fac-
tor (EHF): forward: 5′-GGTGTAATGAATCTCAACCC-3′; reverse:




PC-3 prostate cancer cells were either left untreated (control) or
treated with UNBS5162 at 1) 1, 2) 10, or 3) 1 μM once a day for
5 consecutive days (with a washout process and renewal of culture me-
dium before each new addition of compound, i.e., “5 × 1” μM). Cells
were scraped into cold PBS buffer (for RNA extraction) 72 hours after
the last addition of UNBS5162 into the PC-3 culture medium. Full
genome-wide analyses were performed at the VIB MicroArray Facility
(UZ Gasthuisberg, Catholic University of Leuven, Leuven, Belgium)
using the Affymetrix Human Genome U133 set Plus 2.0 (High
Wycombe, UK).
Microarray Data Analysis
In addition to R, an open-source software environment for statis-
tical computing [15], a set of functions called BioConductor [16] was
used for the analysis and comprehension of the genomic data. The
quality controls in the Affymetrix microarray experiments were per-
formed with the Simpleaffy package and agreed with Affymetrix
guidelines [17]. The background correction, expression quantifica-
tion and normalization were performed using Robust Multichip
Analysis [18]. To select differentially expressed genes between two
experimental conditions, probes for which no overlap occurred be-
tween intervals in the expression values obtained for each condition
were first identified. The fold change between two experimental con-
ditions was computed for each of these probes (without any value
overlap) as the ratio between the two nearest unlog expression values
observed for the two different conditions (i.e., the ratio closest to 1
between any two values from the two different conditions). Probes
for which these ratios were above 2.0 or below 0.50 were then selected.
The annotations of the genes finally selected in this way were retrieved
from the Affymetrix Web site through the BioConductor package
ghgu133plus2.h The EASE software package downloaded from
http://david.niaid.nih.gov/david/ease.htm [19] was used to gather bio-
logic information on the genes detected as over-expressed or down-
regulated by the microarray analysis. This software package was then
used to rank functional clusters by means of the statistical overrep-
resentation of individual genes in specific categories relative to all the
genes in the same category on the microarray.
Western Blot Analysis
Cell extracts were prepared by the lysis of subconfluent PC-3 cells
directly in boiling lysis buffer (10 mM Tris, pH 7.4, 1 mM Na3O4V,
1% SDS, pH 7.4). Approximately 40 μg of extracted proteins (eval-
uated by the bicinchoninic acid protein assay; Pierce, Perbio Science,
Erembodegem, Belgium) was then loaded onto a denaturing poly-
acrylamide gel. The proteins submitted to Western blot analyses were
detected using primary antibodies provided by: 1) CST Technolo-
gies, Bioké, Leiden, The Netherlands: Rb (1:2000) and p-Rb
(1:1000); 2) BD Transduction Laboratories, Erembodegem, Belgium:
E2F1 (1:400); and 3) AbCam, Cambridge, UK: tubulin (1:3000, used
as a loading control). The antibody for LC-3 protein (1:500) was kindly
provided by Dr. Yasuko Kondo. Western blot analyses were performed
as detailed previously [20].
Enzyme-Linked Immunosorbent Assays (ELISAs)
Two different Quantikine ELISA kits (R&D Systems, Abingdon,
UK) for the quantification of human CXCL1 and CXCL8 (IL-8)
were used in this study in accordance with the manufacturer’s in-
structions. Cell culture supernatants were collected after different
treatments and periods, with multiple aliquots taken and stored at
−20°C until analysis.
Assessment of Potential Hematotoxicity of UNBS5162
Investigation of the hematotoxic potential of UNBS5162 was un-
dertaken by HemoGenix (Colorado Springs, CO). The effects of
UNBS5162 on stem and progenitor cell populations from murine
and human bone marrow were assessed using HALO (Hematopoietic/
Hematotoxicity Assay through Luminescence Output) technology.
Stem and hematopoietic progenitor cell populations were isolated
from mouse and human bone marrow samples, plated at a concen-
tration of 1.0 × 104 cells/well and cultured for 5 and 7 days, respec-
tively, in the presence of growth factors and increasing concentrations
of UNBS5162 ranging from 0.5 nM to 50 μM. The proliferative or
growth potential of cell populations was determined from intracellu-
lar ATP (iATP) concentrations and a luciferin/luciferase biolumines-
cence signal detection system. All samples were assayed in eight
replicates. The results are presented as estimated inhibitory concentration
(IC) values.
In Vivo Experiments Using Human Prostate Cancer PC-3 and
DU-145 Xenografts
Orthotopic xenografts were obtained by injecting 2.5 × 106 human
PC-3 or DU-145 cells into the prostate of 6-week-old male nu/nu
mice (n = 9 animals per treatment group). All grafts were performed
under anesthesia [saline / Rompun (Bayer, Leverkusen, Germany) /
Imalgene (Merial, Lyons, France); 5:1:1 by volume]. The end point in
these orthotopic experiments was the survival period of the tumor-
bearing mice after the administration of UNBS3157, UNBS5162, or
reference anticancer agents (taxol, mitoxantrone, and amonafide).
However, for ethical reasons, animals were killed when 20% of body
weight had been lost compared to that determined at the time of
tumor grafting. All animals were weighed three times a week. Au-
topsies and histologic diagnoses were performed on each mouse to
confirm the presence of tumor development; 100% was achieved.
In the case of UNBS5162 experiments in the PC-3 model, after
the sacrifice of animals, tumors were removed from both drug-treated
[10 mg/kg, intravenous (i.v.)] and vehicle-treated mice, fixed in buff-
ered formalin, embedded in paraffin, and 5-μm-thick sections taken.
These histologic slides were then stained with hematoxylin and eosin
for blood vessel counts.
All the in vivo experiments described in the current study were
performed on the basis of authorization No. LA1230509 of the An-
imal Ethics Committee of the Belgian Federal Department of Health,
Nutritional Safety, and the Environment.
In Vitro Characterization of UNBS3157 Stability
To assess the in vitro stability of UNBS3157, 4.7 mg of the com-
pound (Batch No. 27) was added to a 100-ml volumetric flask
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containing 25 ml of a mixture of physiological saline/DMSO (95:5 v/v).
The volume was adjusted to 100 ml with further saline/DMSO
(95:5 v/v) to give a final UNBS3157 concentration of 10−4 M. The
solution was placed in a thermostat-controlled water bath maintained
at 37°C. One-milliliter aliquots of incubate were taken at times 0,
30, 105, 135, 160, 200, 240, 270, 320, 390, and 1320 minutes
and were analyzed as described below; thereafter, the levels of
UNBS3157, UNBS5162, and amonafide were determined. The ki-
netics of UNBS3157 degradation in vitro were determined by
HPLC-UV (250 nm) analysis, using an Atlantis (Waters Corp, Milford,
MA) dC18 5 μm, 4.6 × 150 mm analytical column, and a binary gra-
dient system involving the following: mobile phase A, 0.1% aqueous
formic acid; and mobile phase B, 0.05% formic acid in acetonitrile.
The following gradient was applied at room temperature and pressure:
1) 100% A/0% B to 80% A/20% B in 6 minutes
2) 80% A/20% B to 0% A/100% B in 3 minutes
3) 0% A/100% B to 100% A/0% B in 7 minutes.
UNBS3157, UNBS5162, and amonafide had retention times of
11.25, 6.05, and 5.76 minutes, respectively. The relative amounts
of each compound were determined by comparison of peak areas as-
suming the same response coefficient for all compounds. The starting
material (UNBS3157) was determined to be 98.6% pure but
contained 1.4% residual amonafide resulting from incomplete con-
version to UNBS3157 during the synthetic process [8]. The level of
UNBS5162, if present in the starting material, was below the limit of
detection of the method.
Determination of UNBS5162 Mouse Pharmacokinetics
Mouse in-life phase. Female B6D2F1 mouse (Charles River,
L’Arbresle, France) were administered a single i.v. bolus injection
of 20 mg/kg or a single oral dose of 80-mg/kg UNBS5162 as a solu-
tion (formulated in 0.5% lactic acid). Dosing volume was 10 ml/kg
body weight. The i.v. injection was performed through the tail vein,
and the oral dose was given by gavage. Blood sampling for pharma-
cokinetic analysis was performed by cardiac puncture after Nembutal
intraperitoneal injection. The blood was collected over Li-heparin at
0.05, 0.08, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 2, 4, 7, 16, and 24 hours
after dose. Five animals were used per time point. Blood was kept on
ice for a maximum of 2 hours before isolating plasma by centrifuga-
tion, and the resulting plasma was stored at approximately −70°C
until analysis. The samples were subsequently analyzed for UNBS5162
by liquid chromatography–mass spectrometry.
Bioanalytical method. Plasma concentrations of UNBS5162 were
determined using liquid chromatography–mass spectrometry. The
assay was shown to be linear, precise, and accurate within an analyt-
ical range from 10 to 1000 ng/ml (for the i.v. analytical batch) and
from 5 to 500 ng/ml [for the per os (p.o.) analytical batch]. Briefly,
solid phase extraction was performed using SPE Oasis HLB columns
of 1 ml (Waters). UNBS5162 and the internal standard UNBS5181
were eluted using methanol, evaporated to dryness and reconstituted
in starting solvent, a mixture (90:10 v/v) of 0.05% aqueous formic
acid (mobile phase A) and 0.05% formic acid in acetonitrile (mobile
phase B). Liquid chromatographic separation was effected using an
Atlantis T3 column (50 × 2.1 mm; 3 μm), with an isocratic method
with a 90:10 v/v ratio of mobile phases A/B at a flow rate of 250 μl/min
for 12.5 minutes, followed by 2 minutes of 100% mobile phase B and
then 4.5 minutes reconditioning with the starting solvent at a flow rate
of 250 μl/min. Compound detection and quantification were per-
formed by positive ion electrospray ionization on a QToF Ultima mass
spectrometer (Micromass, Manchester, UK).
Statistical Analyses
Data are expressed as means ± SEM. Data obtained from independent
groups were compared by the nonparametric Kruskall–Wallis (more than
two groups) or Mann–Whitney U tests (two groups). The standard sur-
vival time analyses were carried out using the Kaplan–Meier curves and
the log rank test. The statistical analysis was performed using Statistica
software (Statsoft, Tulsa, OK).
Results
UNBS3157 Displays Antitumor Activity In Vivo in
Orthotopic Human Prostate Cancer Models
The anticancer activity of UNBS3157 versus that of amonafide,
mitoxantrone, and taxol, the latter two drugs approved for the treat-
ment of hormone refractory prostate cancer, has been compared in
the two orthotopic models of human hormone refractory prostate
carcinoma developed in our group, namely PC-3 and DU-145 [21].
Figure 1A morphologically illustrates the typical development of a
human PC-3 orthotopic xenograft 2 weeks after tumor cell grafting
into the prostate of immunocompromised mice.
In the PC-3 model, mitoxantrone failed to contribute any therapeutic
benefit while revealing itself to be highly toxic at 2.5 mg/kg i.v.
(Figure 1B). UNBS3157 displayed appreciable activity against PC-3
prostate carcinoma when administered orally at 160 mg/kg (%T/C:
151%, P = .03; Figure 1B) but not at the lower dose of 40 mg/kg
(%T/C: 100%; data not shown). Amonafide (%T/C: 103% and
107%) at 40 mg/kg p.o. (higher doses were toxic; data not shown)
was not active orally in this aggressive prostate cancer model (Figure 1B).
In the DU-145 model, amonafide was inactive at 20 mg/kg i.v. and
at lower doses (data not shown), whereas UNBS3157 at 20 mg/kg i.v.
(%T/C: 143%, P = .01) and taxol also at 20 mg/kg i.v. (%T/C:
146%, P = .007) contributed a therapeutic benefit (Figure 1C ). Fur-
thermore, both amonafide (%T/C: 138%, P = .04) and UNBS3157
(%T/C: 164%, P = .03) contributed a significant therapeutic benefit
when administered orally at 40 mg/kg (Figure 1D) but not at lower
doses (data not shown). The therapeutic benefit contributed by taxol
at 20 mg/kg i.v. did not significantly (P > .05) differ from that con-
tributed by UNBS3157 at 40 mg/kg p.o. (Figure 1D).
UNBS3157 Is Hydrolyzed to UNBS5162 with No Generation
of Amonafide
UNBS3157 is rapidly and extensively hydrolyzed in saline in vitro
to UNBS5162 (90% in 270 minutes), without production of amona-
fide. Indeed, the level of amonafide remains constant at 1.4% dur-
ing the 22-hour incubation period (Figure 2A). UNBS5162 must
therefore be considered the major in vitro hydrolysis product of
UNBS3157. Of note, 5% DMSO (used for compound solubilization
in different activity assays) did not increase the rate of hydrolysis. The
study of UNBS5162’s metabolism in vivo is currently ongoing.
UNBS5162 Displays Weak In Vitro Antiproliferative Activity
UNBS3157 and UNBS5162 display weak antiproliferative activ-
ity in vitro. Indeed, the mean antiproliferative activity IC50 values
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determined against nine human cancer cell lines investigated (using
the MTT colorimetric assay) were 19.8 and 17.9 μM for UNBS3157
and UNBS5162, respectively (Table 1).
UNBS5162 Mouse Pharmacokinetics
The pharmacokinetic profiles of UNBS5162 in female mice after
i.v. (20 mg/kg) and oral (80 mg/kg) administration are shown in
Figure 2B, and the derived pharmacokinetic parameters are presented
in Table 2. Below limit of quantification values were included in the
pharmacokinetic calculations as 0. Systemic exposure after oral admin-
istration of 80 mg/kg was relatively low (Cmax = 510 ng/ml and
AUC0–∞ = 886 ng·h/ml) reflected in an absolute bioavailability calcu-
lated to be only 3.84%. The volume of distribution (Vd) and the total
clearance were estimated to be 18.9 L/kg and 3.47 L/h per kilogram, re-
spectively. The half-life after i.v. administration of 20-mg/kg UNBS5162
was estimated to be 3.8 hours. As shown in Figure 2B, post–i.v.
UNBS5162 plasma levels of 10 μM are only maintained for approxi-
mately 30 minutes, whereas 1-μM levels are sustained for maximally
2 hours.
UNBS5162 Increases the Therapeutic Benefits of Taxol In Vivo
in the Orthotopic Human PC-3 Prostate Cancer Model
Given that UNBS3157 is rapidly hydrolyzed to UNBS5162
(Figure 2A) and the latter is poorly systemically available after the
oral dose (Figure 2B, open triangles), the anticancer activity of
UNBS5162 was assessed by the i.v. route only. Although 1)
UNBS5162 displays weak antiproliferative activity in vitro (Table 1)
and 2) UNBS5162 plasma concentrations only range between ∼5.0
and 0.5 μM up to 2 hours after dose when administered i.v. at
20 mg/kg to mice (Figure 2B), repeat i.v. administration of the com-
pound at 10 mg/kg (three times a week for 6 consecutive weeks)
contributed therapeutic benefits that were similar to repeat i.v. ad-
ministration (once a week for 6 consecutive weeks) of 20-mg/kg
taxol in the PC-3 orthotopic model (Figure 2C ). Preliminary data
Figure 1. In vivo UNBS3157-mediated antitumor effects. (A) Typical morphologic illustration of an orthotopic model of refractory pros-
tate cancer using the PC-3 cell line. NPT indicates normal prostate tissue. (B–D) A comparison of the activity of UNBS3157 versus that
of amonafide, mitoxantrone, and taxol in two orthotopic models of human hormone refractory PC-3 and DU-145 prostate carcinomas.
Drug administration began 7 days after tumor cell graft, which means that the treatment began when the tumors had already begun to
grow. All compounds were administered using a schedule of three administrations per week (i.e., week 1: days 7, 9, and 11, etc.) for
4 weeks. The control mice that received the vehicle are represented by black circles. Each treatment group contained nine animals. (B)
Compound-induced effects on the survival of PC-3 orthotopic xenograft-bearing mice. UNBS3157 (160 mg/kg) and amonafide (40 mg/kg)
were administered orally, whereas mitoxantrone was administered i.v. at a dose of 2.5 mg/kg. (C and D) UNBS3157-induced effects on
the survival of DU-145 orthotopic xenograft-bearing mice. UNBS3157 and amonafide were administered at 20 mg/kg i.v. (C) or orally at
40 mg/kg (D) with taxol administered in both experiments i.v. only at 20 mg/kg.
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indicated that 10-mg/kg UNBS5162 was a dose as efficacious as
20 mg/kg. We thus decided to use the 10-mg/kg dose for chronic ad-
ministration in xenograft studies in vivo, while keeping the 20-mg/kg
dose in the pharmacokinetics study. Administering UNBS5162 be-
fore or after taxol did not modify the therapeutic benefit contributed
by taxol alone. In sharp contrast, administering UNBS5162 at the
same time as taxol to PC-3 orthotopic tumor-bearing mice signifi-
cantly (P < .01) increased the therapeutic benefit contributed by taxol
alone (Figure 2C ). It is important to emphasize that compound treat-
ment began not on engraftment but after the tumors had taken and
showed considerable growth. Thus, the obtained data relate to de-
creases in tumor growth and metastatic processes in these orthotopic
Table 1. IC50 (μM) Values for In Vitro Growth Inhibition of Human Cancer Cell Lines By
UNBS3157 and UNBS5162.
Compounds Cell Lines
PC-3 DU-145 U373-MG Hs683 HCT-15 LoVo MCF-7 A549 Bx-PC-3
UNBS3157 15.1 23 3.9 9.9 29.3 26.4 44.3 8.7 17.2
UNBS5162 17.3 16 4.7 8.5 28.8 8.9 46.5 21.2 9.1
IC50 values correspond to concentrations that reduced by 50% the global growth of the tested cell
lines after 3 days of culturing in presence of the compounds.
IC50 values reported are the means calculated from six separate determinations. The SEM values
are not reported for the sake of clarity. Additionally, it should be noted that the highest SEM value
calculated was less than 5% of its mean value.
Figure 2. UNBS5162 is the major hydrolysis product of UNBS3157. (A) In vitro rapid and extensive hydrolysis of UNBS3157 to
UNBS5162. The kinetics of UNBS3157 degradation in vitro were determined by HPLC-UV (250 nm) analysis, using an Atlantis (Waters)
dC18 5 μm, 4.6 × 150 mm analytical column, and a binary gradient system involving: mobile phase A: 0.1% aqueous formic acid and
mobile phase B: 0.05% formic acid in acetonitrile; as fully described in the Materials and Methods section. (B) UNBS5162 plasma levels
after a single i.v. bolus injection to mice at 20 mg/kg (black triangles) or after a single oral dose of 80 mg/kg (open triangles) of
UNBS5162 as a solution in aqueous 0.5% lactic acid. The data are presented as means ± SEM. (C) UNBS5162-mediated in vivo effects
on the survival of mice bearing orthotopic xenografts of PC-3 prostate cancer cells. All drug treatments started on the 14th day post–
tumor cell implantation into the prostate of immunocompromised mice enabling full tumor development before any treatment. Com-
pounds were administered as follows: 1) UNBS5162 repeat i.v. administration (three times a week for 6 consecutive weeks) at 10 mg/kg
(open squares), 2) taxol repeat i.v. administration (once a week for 6 consecutive weeks) at 20 mg/kg (open rhombus), 3) UNBS5162
coadministered at the same time as taxol (open triangles) or 4) after taxol (open circles) at the dose regimens specified previously, and 5)
UNBS5162 given three times a week for 6 weeks at 10 mg/kg i.v., followed by 3 additional weeks of 20 mg/kg i.v. taxol at one dose
per week (black stars). The control mice which received vehicle alone are represented by black circles. Each treatment group contained
nine animals. (D) The effects of UNBS5162 alone or in combination with taxol on mouse body weight as an assessment of compound-
associated toxic side effects. The data are presented as means ± SEM.
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models. Combined treatment with taxol and UNBS5162 did not con-
tribute higher toxicity (as monitored by mouse weight measurements
three times a week during the duration of the experiment and through
observation of mouse behavior) than single treatment with
UNBS5162 or taxol alone (Figure 2D).
Furthermore, in an evaluation of potential hematotoxicity,
UNBS5162 at concentrations higher than 1 μM was toxic, as indi-
cated by inhibited proliferation of murine and human hematopoietic
stem and progenitor cells (Table 3).
Characterization of UNBS5162 Mechanism of Action with
Respect to Cell Proliferation and Cell Death
Use was made of computer-assisted phase-contrast microscopy
(quantitative videomicroscopy [22]) in the attempt to elucidate an
overall picture of UNBS5162’s mechanism of action. Six days of ob-
servation revealed that 10 μM UNBS5162 prevented PC-3 cell pop-
ulation development in vitro (Figure 3Ab) compared with control
conditions (Figure 3Aa). In addition, 10 μM UNBS5162 caused a
marked enlargement in PC-3 cells by the end of the 6-day treatment
period compared with the start of the experiment (as indicated in the
activated video; Figure 3Ab). Similar features were observed on treat-
ing DU-145 prostate cancer cells with 10 μM UNBS5162 (data not
shown). However, at 1 μM, UNBS5162 induced no detectable
changes in PC-3 and DU-145 cell dynamics as revealed by quanti-
tative videomicroscopy (data not shown).
Flow cytometry analysis revealed that treatment of PC-3 and DU-
145 cells with 10 μM UNBS5162 for 72 hours markedly blocked
PC-3 cells in their G2 cell cycle phase (Figure 3Ba) and to a lesser
extent in DU-145 cells (Figure 3Bb). Indeed, as shown in Figure 3Ba,
when treated with 10 μM UNBS5162, the percentage of PC-3 cells
in the G2/M phase markedly increased; accordingly, the percentage
of cells in the G1 phase diminished. However, UNBS5162 at 1 μM
did not significantly (P > .05) modify PC-3 (Figure 3Ba) or DU-145
(Figure 3Bb) cell cycle kinetics. Furthermore, chronic treatment of
PC-3 cells with 1 μM UNBS5162 for 5 days (“5 × 1”: cells treated
in vitro for 24 hours with 1 μM UNBS5162 and the culture me-
dium replaced by fresh medium containing 1 μM UNBS5162 every
24 hours for a total of 5 consecutive days) or 3 weeks (“3w1”: cells
treated in vitro for 24 hours with 1 μM UNBS5162 and the culture
medium replaced by fresh medium containing 1 μM UNBS5162
every 24 hours for a total of 3 consecutive weeks) did not notably
modify PC-3 (Figure 3Ba) cell cycle kinetics. In addition to cell
cycle arrest evidenced by flow cytometry, cellular imaging studies
showed that UNBS5162 induced delayed growth and modified cel-
lular morphology in human PC-3 and DU-145 prostate cancer cells,
suggesting that this compound might be able to induce senescence; a
permanent cell growth arrest. Campisi [23] reports that although
specific mechanisms are as yet unknown, the senescence response
seems to result in a reorganization of chromatin, at least some aspects
of which require pRb activity. Replicatively, senescent cells develop
dense foci of heterochromatin [24,25], which coincide with pRb-
dependent heterochromatic repression of genes encoding cyclins
and other positive cell cycle regulators [23]. Many of these repressed
genes are activation targets of E2F transcription factors, some of
which are converted to transcriptional repressors when complexed
with pRb [23]. The E2F family of transcription factors plays an im-
portant role in cell cycle progression [26]. E2F-1, in heterodimeric
complex with another protein, DP-1, is normally inactive because it
is bound to hypophosphorylated pRb [26]. When cells progress from
the G1 to the S phase, pRb becomes hyperphosphorylated and re-
leases the bound E2F-1/DP-1 heterodimer [26]. Treatment of PC-3
cells with 10 μM UNBS5162 completely abolished Rb protein ex-
pression after 48 and 72 hours of treatment. This resulted in the
complete dephosphorylation of pRb at the PSer795 position (Fig-
ure 3C ) and at positions PSer780 and PSer807/11 (data not shown),
with the further consequence of a dramatic decrease in E2F1 expres-
sion at both the protein (Figure 3C ) and mRNA (Figure 3D) lev-
els. Very similar features were observed in DU-145 prostate cancer
cells, but less marked, particularly at the level of cell cycle kinetics
(Figure 3Bb) and with respect to a decrease but not the complete
disappearance of Rb protein (Figure 3C ) and E2F1 (Figure 3, C
and D) expression. UNBS5162 at 1 μM induced no marked mod-
ifications in Rb, pRb, and E2F1 protein expression (Figure 3C ).
The enlargement of PC-3 cells revealed by quantitative videomi-
croscopy on treatment with 10 μMUNBS5162, as shown in Figure 3A,
prompted an investigation whether the compound at this concentration
could induce senescence in these cells. Human PC-3 and DU-145 pros-
tate cancer cells cultured in 0 or 10 μM UNBS5162 or 20 nM Adria-
mycin for 72 hours were evaluated by SA-β-Gal staining. The data
illustrated in Figure 4A clearly indicate that 10 μM [but not 1 μM (data
not shown) or 5 × 1 μM] UNBS5162 induced marked expression of
SA-β-Gal in DU-145 but not in PC-3 cells. “5 × 1 μM” in Figure 4A
indicates that tumor cells were treated in vitro for 24 hours with 1 μM
UNBS5162 and the culture medium was replaced by fresh medium
containing 1 μM UNBS5162 every 24 hours for a total of five consec-
utive days, with determination of senescence being performed 72 hours
after the fifth treatment of cells with UNBS5162. TMZ, as an inducer
of autophagy but not of senescence, was used as a negative control.
Table 2. Pharmacokinetic Parameters in Female Mice After Single i.v. and Oral Administration of UNBS5162.
Route/dose Tmax (h) Cmax (ng/ml) AUC0–∞ (ng·h/ml) T1/2 (h) Vd (L/kg) Cl (L/h per kilogram) F (%)
i.v./20 mg/kg NA 12,009 5767 3.8 18.9 3.47 NA
p.o./80 mg/kg 0.3 510 886 NC NA NA 3.84
AUC indicates area under the curve; Cl, clearance from plasma; Cmax, maximum concentration; F, absolute bioavailability; NA, not applicable; NC, not calculable; T1/2, half-life time; Tmax, time to
maximum concentration; Vd, volume of distribution.
Table 3. Hematoxicity Assay: Estimated IC Values.
CFC-GEMM BFU-E GM-CFC Mk-CFC
Mouse
IC50 (μM) 6.22 5.53 7.04 5.94
IC75 (μM) 7.48 7.03 9.09 7.53
IC90 (μM) 8.96 9.11 12.0 9.61
Human
IC50 (μM) 2.57 3.6 3.74 4.05
IC75 (μM) 5.67 8.16 8.12 9.22
IC90 (μM) 12.8 17.6 19.9 20.1
BFU-E indicates burst-forming unit–erythroid; CFC-GEMM, colony-forming cell – granulocyte,
erythroid, macrophage, megakaryocyte; GM-CFC, granulocyte-macrophage colony-forming cell;
Mk-CFC, megakaryocyte colony-forming cell.
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Moderate concentrations of doxorubicin (ADR, 30 nM) induce senes-
cence in wild type and in p53-mutated human cancer cells [27]; accord-
ingly, the compound was used as a positive control in our experiments
and was found to be active at 20 and 50 nM. Limited SA-β-Gal expres-
sion was observed in PC-3 prostate cancer cells stimulated for 72 hours
with either 10 μM UNBS5162 or with Adriamycin. A possible reason
why PC-3 cells do not stain for SA-β-Gal is that p53 is deleted in these
cells [28], whereas it is mutated in DU-145 cells [8].
In the process of identifying senescence-associated genes in pros-
tate cancer cells, Park et al. [29] found significant suppression of the
EHF in cancer cells in a state of DNA damage-induced senescence.
They also showed that the EHF provides substantial drug resistance
Figure 3. UNBS5162-induced effects at the level of cell proliferation. (A) Still pictures obtained from 6 days computer-assisted phase-
contrast microscopy analysis of untreated (Aa) and 10 μM UNBS5162-treated PC-3 cells (Ab). A double click on panel Aa or Ab will
activate the videos (recordings of the 6-day observation period that have been speeded up to approximately 1 minute). To minimize
the file size of the generated video clips, they have been compressed using the DivX codec. The codec and a movie player are available
at http://divx.com. (B) UNBS5162-induced effects on cell cycle parameters. Flow cytometry analyses of PC-3 (Ba) and DU-145 (Bb) cells
left untreated or treated with 1 and 10 μM UNBS5162 for up to 72 hours. PC-3 cells were assessed also on chronic treatment with
UNBS5162 (i.e., 1 μM each day for 5 days, “5 × 1” and 1 μM each day for 3 weeks, “3w1”). The open bars represent the proportion
of cells in the G0/G1 phase of their cell cycle, whereas the gray and black bars represent the proportion of cells in the S and G2/M phases,
respectively. Each experiment was carried out in triplicate. The data are presented asmeans±SEM. (C) 1 and 10 μMUNBS5162-mediated
effects on Rb protein expression and phosphorylation, and on E2F1 protein expression as evaluated by immunoblot analysis. Tubulin
immunoblot was used as the loading control. (D) 1 and 10 μM UNBS5162-mediated effects on E2F1 mRNA accumulation as evaluated
by quantitative RT-PCR analysis. The data are presented as themeans± SEMof triplicate samples and expressed as the number of copies
per nanogram of column-purified cDNA.
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Figure 4. Determination of UNBS5162-mediated effects on senescence induction in human prostate cancer cells. (A) The results of
senescence evaluation are presented in terms of the % of β-Gal–positive cells in a given cell population (gray bars for PC-3 cells and
black bars for DU-145 cells). Each condition was evaluated in triplicate. The data are presented as the % mean ± SEM of β-Gal–positive
cells after the treatments indicated. “5 × 1 μM” means that tumor cells were treated in vitro for 1 day with 1 μMUNBS5162 and then the
culture medium was replaced by fresh medium containing 1 μM UNBS5162; this procedure of renewal of cell medium containing 1 μM
UNBS5162 was repeated for 5 consecutive days, with determination of senescence being performed 72 hours after the fifth treatment
of tumor cells with UNBS5162. All other treatments lasted for 72 hours before senescence assessment. ADR indicates Adriamycin
(doxorubicin); TMZ, temozolomide. (B) Determination of UNBS5162-mediated effects on EHF mRNA accumulation as evaluated by
quantitative RT-PCR. The data are presented as the means ± SEM of triplicate samples and expressed as the number of copies
per nanogram of column-purified cDNA. (C) UNBS5162-induced apoptotic effects as evaluated by flow cytometry with Annexin V–FITC
staining of PC-3 (gray bars) or DU-145 (black bars) cells after they have been treated for 72 hours with 0 (Ct, untreated cells), 1, or 10 μM
UNBS5162 and evaluated for early apoptotic events [Ca; as revealed by Annexin V (+) and PI (−) staining] and late apoptosis + necrosis
[Cb, as revealed by Annexin V (+) and PI (+) staining]. (Cc) Detection of apoptotic events after the chronic treatment of PC-3 cells with
1 μM UNBS5162. (D) UNBS5162-induced proautophagic effects as evaluated by quantification of acidic vesicular organelles (revealed as
red fluorescent staining) after acridine orange staining of PC-3 (gray bars) or DU-145 (black bars) cells after they have been treated for
72 hours with 0 (Ct, untreated cells), 1, or 10 μM UNBS5162 (Da). (Db) Cell lysates of PC-3 and DU-145 human prostate cancer cells
treated for 72 hours with 0, 1, and 10 μMUNBS5162 were analyzed by Western blot analysis for LC3-I/II expression. Tubulin was used as
the loading control. (Dc) Detection of proautophagic effects (revealed as red fluorescent staining) after the chronic treatment of PC-3
cells with 1 μM UNBS5162.
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in PC-3 prostate cancer cells by inhibiting senescence and cell cycle
arrest. Knockdown of EHF by small interfering RNA inhibited cell
proliferation and induced a premature cellular senescence character-
ized by hypophosphorylation of Rb and increased level of p27, with
concomitant decreases of cyclin A, cdc2, and E2F1 [29]. The data in
Figure 4B show that 72 hours after treatment with UNBS5162 at
10 μM but not at 1 μM, there was a marked sustained decrease in
EHF mRNA levels in DU-145 but not in PC-3 prostate cancer cells.
However, UNBS5162 at 1 μM markedly decreased EHF mRNA ex-
pression in a transient manner in DU-145 cells (Figure 4B).
Amonafide and several analogues are known topoisomerase II in-
hibitors that induce apoptosis [30]. We have already demonstrated
that UNBS3157, the precursor of UNBS5162, is not a topo II poi-
son but is a weak DNA-intercalating agent that does not induce
apoptosis in prostate cancer cells [8]. Furthermore, it is important
to emphasize that the data received from the National Cancer Insti-
tute (NCI) clearly indicate that UNBS5162 and UNBS3157 have a
markedly distinct profile to amonafide. In this study, using flow cy-
tometry, we show that UNBS5162 does not induce real (early) apop-
tosis in PC-3 (Figure 4Ca, gray bars) or in DU-145 cells (Figure 4Ca,
black bars). As depicted in Figure 4Cb, UNBS5162 induces late apop-
totic and necrotic events in DU-145 cells that could have resulted
from compound-induced proautophagic effects or senescence ob-
served in this cell line (Figure 4, A and Da–Db). Indeed, using flow
cytometry techniques for quantification of acidic vesicular organelles
(autophagic vacuoles), it was possible to observe that UNBS5162 at
10 μM had a proautophagic effect in both cell lines (Figure 4Da).
These cancer cell lines were then further evaluated to quantify the
expression of light chain 3 cytosolic protein (LC3-I) and its processed
light chain 3 membrane-bound form (LC3-II); a specific marker of
autophagy. An immunoblot analysis technique was used to assess for
autophagy as indicated by the LC3-II marker. UNBS5162 at 10 μM
induced the up-regulation of LC3-II protein in the DU-145 cell
line only (Figure 4Db); a feature that could partly explain why
UNBS5162 induced weaker proautophagic effects in PC-3 cells. Al-
though these data suggested that UNBS5162 induces autophagy-
related effects in DU-145 and PC-3 cells, they did not confirm that
UNBS5162 actually kills cancer cells by means of autophagy-related
cell death. The possibility remained at this stage of our investigations
that human prostate cancer cells might be defending themselves
against the adverse effects of UNBS5162 by activating autophagy-
related mechanisms of defense. Indeed, cells that undergo excessive
autophagy are induced to die in a nonapoptotic manner [31], but
cancer cells including human prostate cancer cells can also undergo
autophagy to combat adverse events including chemotherapy [32]
and radiotherapy [33]. The cellular imaging experiments described
below strongly suggest that UNBS5162 does not kill PC-3 and
DU-145 cells but rather irreversibly block their proliferation. Thus,
the proautophagic effects observed in PC-3 and DU-145 cells when
treating them with UNBS5162 correspond to autophagy-related de-
fense mechanisms of these cell lines to the compound, rather than to
actual UNBS5162-induced autophagy-related cell death. Further-
more, it is important to emphasize that chronic treatment of PC-3
cells with 1 μM UNBS5162 did not induce cell death either through
apoptosis (Figure 4Cc) or autophagy-related processes (Figure 4Dc).
In summary, at 10 μM UNBS5162 markedly impairs PC-3 tumor
cell growth kinetics, without inducing senescence, whereas the re-
verse feature is observed with respect to DU-145 cells (Table 4). This
difference might result from their respective p53 status and/or the
extent of p16 expression, which is a positive regulator of pRb and
tumor suppressor in its own right, as reported by Campisi [23]. At
1 μM, UNBS5162 induces no such antitumor effects. Thus, the data
obtained in vitro when human prostate cancer cells are treated once
with either 1 or 10 μM UNBS5162 (Figures 3 and 4; Tables 1 and
4) cannot explain the activity obtained in vivo (Figure 2C ) with
the 10-mg/kg i.v. UNBS5162 regimen, which is likely to be associ-
ated with UNBS5162 plasma levels markedly less than 1 μM a short
time after dosing. In contrast, chronic treatment with 5 × 1 μM
UNBS5162 in vitro reconcile well with the data obtained in vivo.
The presence or otherwise of active UNBS5162 metabolites in vivo
has to be confirmed, and to this effect, an investigation of the com-
pound’s metabolism is currently ongoing.
Genome-wide Analyses to Further Characterize UNBS5162’s
Mechanism of Action
A first set of experiments were performed in vitro using human
PC-3 cancer cells treated with UNBS5162 once over 24 hours either
at 1 or 10 μM, the results of which are illustrated in Table 5A. A
second set of experiments were then performed in which the effects
were analyzed of chronic in vitro treatment with 1 μM (“5 × 1 μM”)
UNBS5162, the results of which are given in Table 5B.
The in vitro treatment of PC-3 cells with a single dose of 10 μM
UNBS5162 markedly modified the nuclear organization and biogen-
esis of these cells by increasing significantly the levels of expression,
at least at the mRNA level, of various types of histones (Table 5A).
Narita et al. [24] described a distinct heterochromatic structure that
accumulates in senescent human fibroblasts, which they designated
senescence-associated heterochromatic foci (SAHF). SAHF forma-
tion coincides with the recruitment of heterochromatin proteins
and the retinoblastoma (Rb) tumor suppressor to E2F-responsive
promoters and is associated with the stable repression of E2F target
genes [24]. Notably, both SAHF formation and the silencing of E2F
target genes depend on the integrity of the Rb pathway and do not
occur in reversibly arrested cells [24]. SAHF is enriched in Macro-
H2a, a transcription-silencing histone H2A variant [34], which is a
hallmark of mammalian heterochromatin [35]. UNBS5162 at 10 μM
markedly increased the levels of heterochromatin in PC-3 cells through
an increase in number of histones, at least at the mRNA levels
(Table 5A). In contrast, UNBS5162 decreased by 2.6-fold the level
of H2AFY mRNA expression which produces macroH2A1.2 [35].
As already emphasized, the data obtained in vitro when human pros-
tate cancer cells are treated once with 10 μM UNBS5162 are unable
to explain the activity evident in vivo (Figure 2C ); however, no further
investigation of the compound’s effects on chromatin remodeling was
undertaken. Of note, some other groups of genes were also affected
Table 4. Summary of 10 μM UNBS5162 Effects In Vitro on Cell Proliferation and Cell Death.
PC-3 (p53 Null) DU-145 (p53 Mutated)
Growth arrest
Quantitative videomicroscopy ++ +
G2 phase blockade (FCM) +++ +
pRb expression (WB) +++ +
E2F1 expression (WB) ++ +




FCM indicates flow cytometry; WB, Western blot.
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by 10 μM UNBS5162 treatment, such as certain pertinent to amino
acid metabolism and endopeptidase inhibitor activity (data not
shown). The in vitro treatment of PC-3 cells with a single dose of
1 μM UNBS5162 did not modify significantly the genomic profile
(Table 5A). In sharp contrast, daily treatment for 5 days with 1 μM
UNBS5162 markedly impaired CXCL chemokine expression
(Table 5B; Figure 5). Single 10 μM treatment with UNBS5162 im-
paired CXCL chemokines expression much less than the chronic treat-
ment with 5 × 1 μMUNBS5162 (Figure 5). ELISA measurements for
CXCL1 (Figure 5C ) and CXCL8 (IL-8; Figure 5D) confirmed at the
protein level, in both PC-3 and DU-145 cells, the data obtained with
PC-3 cancer cells at the mRNA level (Figure 5A; Table 5B). It should
be noted that most of the CXCL chemokines are proangiogenic fac-
tors. Indeed, repeat treatment of mice bearing orthotopic PC-3 xeno-
grafts (three times a week for 6 weeks) with 10-mg/kg i.v. UNBS5162,
as illustrated in Figure 2C, led to a significant decrease in tumor
neoangionesis (Figure 5B), which was evaluated as described elsewhere
[36,37]. Of note, some other groups of genes, such as those pertinent
to the immune response, response to stress, chemotaxis, and cell prolif-
eration, were also affected by chronic (“5 × 1”) UNBS5162 treatment.
Discussion
UNBS3157, a naphthalimide that belongs to the same class as amo-
nafide, was designed to avoid the specific metabolic pathway of amo-
nafide that induces hematotoxicity [8]. The current study shows that
UNBS3157, which has marked antitumor activity in vivo, rapidly and
irreversibly hydrolyzes in vitro to UNBS5162 (Figure 2). We recently
reported that unlike amonafide, UNBS3157 does not display a mech-
anism of action characteristic of an intercalating agent [8]. The NCI
recently investigated UNBS3157 (coded as D-742814 by the NCI)
and UNBS5162 (coded as D-742815) and compared their potential
mechanism of action to those of approximately 750,000 compounds
already available in their database. The NCI concluded that, whereas
the mechanisms of action of UNBS3157 and UNBS5162 were quite
comparable (correlation coefficient 0.78), they were distinct from
those of the 750,000 compounds (unpublished data). The NCI 60
Cell Line Panel analysis indicated that UNBS3157 and UNBS5162
might have the profile of a multidrug resistance P-glycoprotein
(MDR-Pgp) substrate. On investigation, it has been confirmed that
even at 100 μM, UNBS3157 and UNBS5162 do not affect Pgp
ATPase activity (data not shown).
Affymetrix genome-wide microarray analysis and ELISAs have re-
vealed that in vitro incubation of UNBS5162 (1 μM five times a
week) with human PC-3 prostate cancer cells dramatically decreased
(at both mRNA and protein levels) the expression of the proangio-
genic CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL8 che-
mokines, whereas acute administration of 10 μM did not (Table 5
and Figure 5). These data obtained in PC-3 cells were reproduced
in DU-145 cells. Histopathologic analysis additionally revealed anti-
angiogenic properties in vivo for UNBS5162 in the orthotopic PC-3
model (Figure 5). To strengthen the correlation between cytokine
levels and antitumor activity in vivo, a novel set of experiments is
now being conducted (including immunostaining of excised tumors)
to further decipher UNBS5162’s mechanism of action in vivo.
It should be recalled that a complex network of chemokines and
their receptors influences the development of primary tumors and
Table 5. Genome-wide Affymetrix Analysis of Human PC-3 Prostate Cancer Cells Treated In Vitro (A) for 24 hours with a Single Administration of Either 1 or 10 μM UNBS5162 or (B) Chronically
with Five 1 μM Administrations for a Period of 5 Days with the Genomic Analysis Performed 72 hours after the fifth Administration of 1 μM UNBS5162.
System Gene Category List Population EASE Score Bootstrap Score Genes Expression Level: Control vs UNBS5162 at
Hits Total Hits Total 10 μM* 1 μM
(A)
Biological process Nucleosome assembly 11 75 56 10,401 5 × 10−12 0.001 H2AFY 2.6 NA
HIST1H3H 0.3 NA
HIST1H2BD 0.3 NA




DNA packaging 11 75 160 10,401 2 × 10−7 0.001 HIST2H2AA 0.4 NA
H2BFS 0.5 NA
System Gene Category List Population EASE Score Bootstrap Score Genes Expression Level: Control vs UNBS5162 at
Hits Total Hits Total 10 μM 5 × 1 μM* 1 μM
(B)
Molecular function Chemokine receptor binding 11 279 47 10,631 2.8 × 10−7 0.001 CXCL3 2.0 67.6 1.0
CXCL2 2.2 58.4 1.1
CXCL1 1.1 40.9 NA
Chemokine activity CXCL6 NA 39.5 NA
CXCL8 (IL-8) NA 15.7 1.2
CXCL11 3.4 5.0 1.8
CXCL5 1.0 4.8 1.1
CXCL10 2.9 4.2 2.1
System refers to the system of categorizing genes (e.g., “Biologic Process”) in the databases provided by the EASE software package. Gene Category refers to the specific category of genes within the System
(e.g., “nucleosome assembly”). List Hits refers to the number of genes in the list of differentially expressed genes (list_diff resulting from the microarray data analysis) that belong to the Gene Category. List
Total refers to the number of genes in list_diff that belong to any Gene Category within the System. Population Hits is the number of genes in the total group of genes assayed (list_tot) that belong to the
specific Gene Category. Population Total refers to the number of genes in list_tot that belong to any Gene Category within the System. The EASE score is the probability value characterizing the change of
proportion between the two ratios: population hits/population total and list hits/list total. It constitutes the upper band of the distribution of leave-one-out Fisher exact probabilities computed on these
two ratios. The Bootstrap method is an iteratively running overrepresentation analysis on random gene lists to determine true probability more accurately.
NA indicates not available because there is an overlap between the two value intervals.
*Reference condition corresponding to EASE results.
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Figure 5. UNBS5162-induced targeting of CXCL chemokines and impact on angiogenesis. (A) Relative expression levels of CXCL che-
mokine mRNAs in untreated (open bars) and UNBS5162-treated (10 μM for 24 hours, gray bars; 5 × 1 μM, black bars) PC-3 cells, as
evaluated by means of full genome microarray analysis. The data are presented as means ± SEM. (B) UNBS5162-induced in vivo anti-
angiogenic effects after repeat administration (three times a week for 6 weeks) at 10 mg/kg i.v. to mice implanted with PC-3 orthotopic
xenografts. UNBS5162-mediated reduction in angiogenesis in this model was quantified by blood vessel counting of histologic slides
prepared from excised tumors subsequently stained with hematoxylin and eosin (Ba). Ten measurements per sample (from nine mice in
each experimental group) were performed, and the results are expressed as the percentage of the surface area covered by blood ves-
sels from UNBS5162-treated mice compared with untreated control mice (set at 100%). The data are presented as means ± SEM.
Representative slides of untreated (control) excised tumors (Bb) and tumors excised from UNBS5162-treated animals (Bc) after staining
with hematoxylin and eosin for blood vessels counting. (C and D) ELISA determination of CXCL1 (C) and CXCL8 (IL-8; D) protein levels in
untreated and 5 × 1 μM UNBS5162-treated PC-3 (gray columns) and DU-145 (black columns) cells. In UNBS5162-treated experiments,
the supernatants were collected 24 and 72 hours after the last treatment. The concentrations of the two specific chemokines expressed
as picograms per milliliters were normalized by the cell number determined in each sample. Each sample was assessed in triplicate. The
data are presented as means ± SEM.
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metastases [38,39]. Chemokine signaling results in the transcription
of target genes that are involved in cell invasion, motility, interac-
tions with the extracellular matrix, and survival of both normal
and cancer cells [38,39]. The small (8–10 kDa) chemokines are clas-
sified into four highly conserved groups, namely, CXC, CC, C, and
CX3C, based on the position of the first two cysteines that are ad-
jacent to the amino terminus [38,39]. More than 50 chemokines
have been discovered so far, and there are at least 18 human seven–
transmembrane domain chemokine receptors [38,39]. CXC chemo-
kines are a unique cytokine family that exhibit, on the basis of struc-
ture/function and receptor binding/activation, either angiogenic or
angiostatic biologic activity in the regulation of angiogenesis [40].
The glutamic acid–leucine–arginine (ELR+) CXC chemokines [such
as GRO-α/N51/KC (CXCL1), Gro-β/MIP-2α (CXCL2), and IL-8
(CXCL8)] are potent promoters of angiogenesis and mediate their
angiogenic activity through signal coupling of CXCR2 on the endo-
thelium. The proangiogenic members of the CXC chemokines are di-
rectly chemotactic to endothelial cells and cancer cells, which display
the receptors for these CXCL chemokines, and they stimulate angio-
genesis in vivo [38–41]. By contrast, members of the CXC chemokine
family (ELR−), such as platelet factor-4 (PF4; CXCL4) and interferon-
inducible CXC chemokines, are potent inhibitors of angiogenesis and
use CXCR3 on the endothelium to mediate their angiostatic activity. A
number of studies have demonstrated that proangiogenic chemokines
mediate the tumorigenicity of prostate cancer cells [42–45], due at
least partly to constitutively activated nuclear factor-κB/p65 (Rel A)
in human prostate adenocarcinoma, as reported by Shukla et al.
[46]. Also, it has been demonstrated that CXCL8 is not detectable
in androgen-responsive prostate cancer cells but is highly expressed
in androgen-independent metastatic cells, and it functions in androgen
independence, tumor growth, chemoresistance, metastases, and angio-
genesis [47–50]. Furthermore, CXCL1, CXCL3, CXCL5, and
CXCL6 also directly influence the biologic behavior of human prostate
cancer cells [51]. As revealed in the present study and by additional
unpublished data from our laboratory, CXCL9, 10, and 11, which ex-
ert rather antiangiogenic effects [40,41,52], are not expressed or are
only very weakly expressed in human PC-3 and DU-145 prostate can-
cer cells. In contrast, the data from the present study show that
CXCL1, CXCL2, CXCL3, CXCL6, and CXCL8 are expressed at very
high basal levels in human prostate cancer cells and that UNBS5162
administered in vitro in a metronomic approach almost completely
abolished their expression, with impairment of in vivo angiogenesis
as a consequence (see Figure 5). The fact that the antitumor effects
of UNBS5162 are more pronounced when administered repeatedly
at low doses rather than acutely at high doses must be considered in
the light of the studies published by Kerbel et al. with respect to the
fact that metronomic chemotherapy can actually be more effective
than high dose monotherapy [53–55]. The present study demonstrates
that metronomic delivery of a compound, i.e., UNBS5162, even
in vitro, targets clusters of genes that are totally different to those tar-
geted by an acute high dose of the same compound. Repeat in vivo i.v.
administration of UNBS5162 despite an apparent low plasma drug
exposure after 1 to 2 hours also markedly increased the therapeutic
benefits of taxol (Figure 2).
As emphasized by Balkwill [38], chemokines (including CXCL che-
mokines) and their receptors are involved in malignant progression,
and a better understanding of chemokine signaling in this process
could lead to new therapeutic strategies for cancer. As the chemokine
network is complex, it is unlikely that an individual chemokine antag-
onist would have a sufficiently powerful action in cancer [38,39].
Small-molecule antagonists exist for several chemokine receptors
[39]. The present study shows that UNBS5162 is a pan-antagonist
of CXCL chemokine expression that displays antitumor effects in ex-
perimental models of human refractory prostate cancers. The manner
in which UNBS5162 antagonizes CXCL chemokine expression re-
mains unknown, but the present study strongly suggests that this an-
tagonism does not occur at the level of CXCL chemokine receptors.
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